Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma

Table 4 Safety profiles and adverse events, n (%)

Adverse event	Any grade group			Grades 3-4 group
	GemCis group (n = 31)	GemCis + IDA-TACE group (n = 19)	P value	GemCis group (n = 31)	GemCis + IDA-TACE group (n = 19)	P value
Nausea and vomiting	13 (42.9)	14 (73.7)	0.029	0 (0)	1 (5.3)	0.380
Abdominal pain	6 (19.4)	15 (78.9)	< 0.001	2 (6.5)	5 (26.3)	0.049
Myelosuppression	11 (35.5)	8 (42.1)	0.640	6 (19.4)	4 (21.1)	1.000
Fever	7 (22.6)	10 (52.6)	0.029	4 (12.9)	5 (26.3)	0.273
Fatigue	3 (9.7)	4 (21.1)	0.404	0 (0)	0 (0)	1.000
Infections	5 (16.1)	6 (31.6)	0.293	1 (3.2)	2 (10.5)	0.549
Ascites	6 (19.4)	3 (15.8)	1.000	2 (6.5)	1 (5.3)	1.000
Elevated transaminases	9 (29.0)	12 (63.2)	0.018	4 (12.9)	8 (42.1)	0.038
Hyperbilirubinemia	4 (12.9)	8 (42.1)	0.038	0 (0)	1 (5.3)	0.380

IDA: Idarubicin; GemCis: Gemcitabine and cisplatin; TACE: Transarterial chemoembolization.